Clinical Trial Update: Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating subthalamic nucleus gene therapy for Parkinson's disease has completed, providing early safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AAV-GAD gene therapy (glutamic acid decarboxylase gene therapy)

Snippet

Sponsor: Neurologix, Inc. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED